ASCO® 2024 Highlights: Presenter Vignette – Kai-Keen Shiu

Dr. Kai-Keen Shiu

Dr. Kai-Keen Shiu

PhD, FRCP

UCL Cancer Institute

Abstract# LBA3504

NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.